1-20 of 24 results for subject:"Medical equipment"
Librarians' tools
- Search time
- 0.213 seconds
- Solr query time
- 0.007 seconds
- Search query
- subject:"Medical equipment"
- We searched for
- subject_t:"Medical equipment" OR subject_t:"Medical devices" OR subject_ses:91970
Type
House
Session
Year
Department
Member
More
Primary member
More
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health, whether patient uptake of insulin pumps has reached the levels set by the NICE technology appraisal 151 benchmarking tool issued in July 2008; how many people have taken up the use of such pumps; and if he will make a statement.
To ask the Secretary of State for Health, whether patient uptake of insulin pumps has reached the levels set by the NICE technology appraisal 151 benchmarking tool issued in July 2008; how many people have taken up the use of such pumps; and if he will make a statement.
Commissioners and providers should make insulin pumps available for those people with Type 1 diabetes who meet the criteria in the National Institute for Health and Care Excellence’s technology appraisal guidance on continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151) as well as ensuring that relevant structured patient education is provided to support people newly diagnosed with diabetes and at appropriate points in their life as their condition progresses.
Information on the number of people using insulin pumps is not collected centrally.
The United Kingdom Insulin Pump Audit, published in May 2013, collected data from across the United Kingdom. The audit demonstrated that 6% of adults with Type 1 diabetes and 19% of children with Type 1 diabetes were being treated with insulin pumps. The audit’s findings are available at:
www.diabetes.org.uk/Documents/News/The_United_Kingdom_Insulin_Pump_Audit_May_2013.pdf
To ask the Secretary of State for Health what steps he is taking to ensure that insulin pump therapy is available to people with diabetes.
[R]
To ask the Secretary of State for Health what steps he is taking to ensure that insulin pump therapy is available to people with diabetes.
[R]
It is the responsibility of NHS England to ensure that commissioners and providers make insulin pumps available for those people with diabetes who meet the criteria recommended by the National Institute for Health and Care Excellence (NICE).
NICE 2008 guidance recommends pump therapy as an option for adults and children over the age of 12 years with Type 1 diabetes, provided that multiple-daily insulin therapy has failed. It also recommends that insulin pump therapy can be used for children younger than 12 years with Type 1 diabetes, provided specific criteria are met.
Insulin pump therapy is not appropriate for everyone as it requires self-management and regular close monitoring. People who commence insulin pumps need to have a detailed structured education programme and good clinical support to maintain and support them on this therapy. All decisions about insulin pump therapy must be made in consultation between the patient (and/or their parents or carer) and their health care professional.
To ask the Secretary of State for Health how many requests for the funding of insulin pump therapy have been made to individual funding request panels in each year since 2010.
[R]
To ask the Secretary of State for Health how many requests for the funding of insulin pump therapy have been made to individual funding request panels in each year since 2010.
[R]
The National Institute for Health and Care Excellence (NICE) has issued technology appraisal guidance (TA151, June 2008) which recommends continuous subcutaneous insulin infusion (CSII or 'insulin pump') therapy as a treatment option for adults and children with type 1 diabetes mellitus, subject to certain clinical criteria. The therapy is not recommended for the treatment of people with type 2 diabetes mellitus.
For patients not covered by NICE'S recommendations, funding decisions should be made by the relevant national health service commissioner based on an assessment of the available evidence.
Prior to April 2013, primary care trusts were responsible for dealing with individual funding requests and information on individual funding request decisions was not collected centrally.
From April 2013, NHS England assumed responsibility for commissioning specialist endocrinology and diabetes services for children and young people and insulin-resistant diabetes services for adults and children, with clinical commissioning groups (CCGs) responsible for commissioning other diabetes services for adults.
We are advised by NHS England that information on the number of individual funding requests for the funding of insulin pump therapy made to NHS England and CCGs is not collected centrally.
To ask the Secretary of State for Education what steps he has taken since 2010 to ensure that (a) primary and (b) secondary schools are equipped to support children with diabetes.
To ask the Secretary of State for Education what steps he has taken since 2010 to ensure that (a) primary and (b) secondary schools are equipped to support children with diabetes.
Schools are already required to support children with long-term medical conditions such as diabetes. Non-statutory guidance, “Managing Medicines in Schools and Early Years Settings”, is available to schools to help them manage medicines and support children with medical needs such as diabetes.
From September 2014, there will be a new duty, which was introduced in the Children and Families Act 2014, on governing bodies of maintained schools and proprietors of academies to make arrangements to support pupils at school with medical conditions and to have regard to statutory guidance. The guidance, upon which we have consulted publicly, will set out the requirements on schools to support children with medical conditions, which we would expect them to apply to conditions like diabetes.
To ask the Secretary of State for Health which bodies in the NHS have responsibility for funding the replacement of out-of-warranty insulin pumps for paediatric patients with diabetes.
[162009]
To ask the Secretary of State for Health which bodies in the NHS have responsibility for funding the replacement of out-of-warranty insulin pumps for paediatric patients with diabetes.
[162009]
NHS England is responsible for commissioning specialist endocrinology and diabetes services for children and young people as part of its specialised services. This service includes the provision of insulin pumps and replacement pumps where clinically appropriate.
To ask the Secretary of State for Health if he will make it his policy to require the National Institute for Health and Clinical Excellence to consider the costs and benefits to wider society of new and existing medical devices in addition to clinical and economic cost-effectiveness when conducting technology...
To ask the Secretary of State for Health if he will make it his policy to require the National Institute for Health and Clinical Excellence to consider the costs and benefits to wider society of new and existing medical devices in addition to clinical and economic cost-effectiveness when conducting technology...
That this House disagrees with the National Institute for Health and Clinical Excellence's recent technology appraisal document which proposes the restriction of access to inhaled insulin products on the NHS to patients with `a proven injection phobia diagnosed by a psychiatrist or psychologist'; is concerned that diabetes sufferers often delay treatment for as long as four years due to a fear of injections, risking the complications of heart disease, blindness and kidney failure, a situation that will only be compounded by attaching the unfortunate stigma of mental illness to those with a phobia of needles; expresses concern at the additional workload that will be placed on already overstretched NHS psychiatric services; and believes that the judgment of expert clinicians should be trusted in managing each individual patient's condition.
That this House disagrees with the National Institute for Health and Clinical Excellence's recent technology appraisal document which proposes the restriction of access to inhaled insulin products on the NHS to patients with `a proven injection phobia diagnosed by a psychiatrist or psychologist'; is concerned that diabetes sufferers often delay...
That this House disagrees with the National Institute for Health and Clinical Excellence's recent technology appraisal document which proposes the restriction of access to inhaled insulin products on the NHS to patients with `a proven injection phobia diagnosed by a psychiatrist or psychologist'; is concerned that diabetes sufferers often delay treatment for as long as four years due to a fear of injections, risking the complications of heart disease, blindness and kidney failure, a situation that will only be compounded by attaching the unfortunate stigma of mental illness to those with a phobia of needles; expresses concern at the additional workload that will be placed on already overstretched NHS psychiatric services; and believes that the judgement of expert clinicians should be trusted in managing each individual patient's condition.
That this House disagrees with the National Institute for Health and Clinical Excellence's recent technology appraisal document which proposes the restriction of access to inhaled insulin products on the NHS to patients with `a proven injection phobia diagnosed by a psychiatrist or psychologist'; is concerned that diabetes sufferers often delay...
That this House believes a significant lack of education is allowing healthcare professionals and patients alike to become confused as to the best and most effective use of blood glucose monitoring for diabetes and that because the current primary care trust guidelines discourage the prescription of blood glucose strips for self-monitoring, it may become difficult for those in primary care to meet the National Institute for Clinical Excellence-recommended blood glucose target levels; and calls on Her Majesty's Government to ensure that blood glucose monitoring strips are not restricted for type II diabetes patients who are best placed to self-manage their condition.
That this House believes a significant lack of education is allowing healthcare professionals and patients alike to become confused as to the best and most effective use of blood glucose monitoring for diabetes and that because the current primary care trust guidelines discourage the prescription of blood glucose strips for...
That this House believes a significant lack of education is allowing healthcare professionals and patients alike to become confused as to the best and most effective use of blood glucose monitoring for diabetes and that because the current primary care trust guidelines discourage the prescription of blood glucose strips for self-monitoring, it may become difficult for those in primary care to meet the National Institute for Clinical Excellence-recommended blood glucose target levels; and calls on Her Majesty's government to ensure that blood glucose monitoring strips are not restricted for type II diabetes who are best placed to self-manage their condition.
That this House believes a significant lack of education is allowing healthcare professionals and patients alike to become confused as to the best and most effective use of blood glucose monitoring for diabetes and that because the current primary care trust guidelines discourage the prescription of blood glucose strips for...
That this House welcomes the Government's proposal to put refillable insulin pen injection devices and pen needles on prescription and notes that this will benefit over 250,000 people who currently have to purchase their own needles; notes however the serious misgivings of the British Diabetic Association about the proposal to blacklist disposable pens that will deprive an estimated 50,000 diabetics of their chosen method of injecting insulin as disposable pens will become prohibitively expensive if only available privately; and therefore calls on the Government to reflect carefully on representations from medical professionals who are concerned that some among the 50,000 affecting diabetics will not be able to switch to refillable pens without requiring assistance or endangering their health in the absence of such help.
That this House welcomes the Government's proposal to put refillable insulin pen injection devices and pen needles on prescription and notes that this will benefit over 250,000 people who currently have to purchase their own needles; notes however the serious misgivings of the British Diabetic Association about the proposal to...
To ask the Secretary of State for Health, if he will make a statement about the prescribing of pen needles and disposable pens for insulin-dependent diabetics. - Ref to 336 c747W.
To ask the Secretary of State for Health, if he will make a statement about the prescribing of pen needles and disposable pens for insulin-dependent diabetics. - Ref to 336 c747W.
To ask the Secretary of State for Health, when he expects to make an announcement concerning the prescribing of insulin pen needles; and if he will make a statement.
To ask the Secretary of State for Health, when he expects to make an announcement concerning the prescribing of insulin pen needles; and if he will make a statement.
To ask the Secretary of State for Health, what representations he has received on Government proposals on pen needles and insulin injection pens; and if he will make a statement.
To ask the Secretary of State for Health, what representations he has received on Government proposals on pen needles and insulin injection pens; and if he will make a statement.
That this House welcomes the Government's proposal to put refillable insulin pen injection devices and pen needles on prescription and notes that this will benefit over 250,000 people who currently have to purchase their own needles; notes however the serious misgivings of the British Diabetic Association about the proposal to blacklist disposable pens that will deprive an estimated 50,000 diabetics of their chosen method of injecting insulin as disposable pens will become prohibitively expensive if only available privately; and therefore calls on the Government to reflect carefully on representations from medical professionals who are concerned that some among the 50,000 affected diabetics will not be able to switch to refillable pens without requiring assistance or endangering their health in the absence of such help.
That this House welcomes the Government's proposal to put refillable insulin pen injection devices and pen needles on prescription and notes that this will benefit over 250,000 people who currently have to purchase their own needles; notes however the serious misgivings of the British Diabetic Association about the proposal to...
That this House calls upon the Secretary of State for Health to acknowledge that insulin-dependent diabetics will require pen needles throughout their entire lifetime; notes that insulin-dependent diabetics have to care for themselves on a day to day basis; notes that diabetics using pen needles benefit from better control of diabetes and are likely to have fewer complications; notes that pen needles are re-used more often than syringe needles; notes that pen devices are more convenient for use by children, the elderly, the visually impaired and stroke sufferers; notes that the present system whereby some patients are provided with needles free through their diabetic clinics but paid for by the NHS is unfair; and calls for an early review of current policy and for provision of pen needles on prescription for all insulin-dependent diabetics.
That this House calls upon the Secretary of State for Health to acknowledge that insulin-dependent diabetics will require pen needles throughout their entire lifetime; notes that insulin-dependent diabetics have to care for themselves on a day to day basis; notes that diabetics using pen needles benefit from better control of...
To ask the Secretary of State for Health, when he expects to conclude his consideration of making pen needles available on the NHS for insulin dependent diabetics; if he will make a statement about the availability of needles for diabetic pen injection systems through the NHS.
To ask the Secretary of State for Health, when he expects to conclude his consideration of making pen needles available on the NHS for insulin dependent diabetics; if he will make a statement about the availability of needles for diabetic pen injection systems through the NHS.
To ask the Secretary of State for Health, what progress he has made in consideration of whether general practitioners should be allowed to prescribe insulin injection pen needles on the National Health Service. - Ref to 311 c121W, 28 April 1998.
To ask the Secretary of State for Health, what progress he has made in consideration of whether general practitioners should be allowed to prescribe insulin injection pen needles on the National Health Service. - Ref to 311 c121W, 28 April 1998.
Adjournment debate on insulin pen needles.
Adjournment debate on insulin pen needles.
To ask the Secretary of State for Health, what factors are being considered in determining whether pen needles for insulin dependent diabetics should be available on prescription; and what representations he has received about pen needles for the use of insulin dependent diabetics.
To ask the Secretary of State for Health, what factors are being considered in determining whether pen needles for insulin dependent diabetics should be available on prescription; and what representations he has received about pen needles for the use of insulin dependent diabetics.